Hair Million, for hair growth




DreamPharm Products:

Lutein-20||Herbs for headache, fever, and migraine || Milk thistle||Saw palmetto|| Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract|| Ginseng and Ginkgo||Hair Million|| DHEA||Coenzyme Q10|| Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.|| Weight loss herbal formula for menopause and pms||Ginkgo biloba|| Colon cleansing, Laxative||ViaVita, Lecithin for healthy liver

Fatty acids resources:

Pathogen research abs 1 || Pathogen research abs 2 || Pathogen research abs 3 || Pathogen research abs 4 || Pathogen research abs 5 || Hormone and endocrine research abs 1 || Hormone and endocrine research abs 2 || Hormone and endocrine research abs 3 || Hormone and endocrine research abs 4 || Hormone and endocrine research abs 5







Thyroid. 2003 Apr;13(4):341-3.
Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions.

Arturi F, Scarpelli D, Coco A, Sacco R, Bruno R, Filetti S, Russo D.

Dipartimento di Medicina Sperimentale e Clinica and Dipartimento di Scienze Farmacobiologiche, University of Catanzaro, Catanzaro, Italy.

Ten years after the first description of activating mutations in the thyroid stimulating hormone receptor (TSHR) gene in sporadic autonomous hyperfunctioning thyroid adenomas, there is general agreement in assigning a major pathogenic role of this genetic abnormality, acting via the constitutive activation of the cAMP pathway, in both the growth and functional characteristic of these tumours. From the beginning, however, the pathophysiological and clinical relevance of somatic TSHR mutations has been debated and some arguments still exist against a fully causative role of these mutations and the practical value of detecting these mutations for the diagnosis, treatment and prognosis of thyroid hot nodules. Some major issues will be examined herein, including (a) the frequency of TSHR alterations in various reports showing that the genetic abnormality underlying the pathogenesis of a substantial subset of thyroid tumours has yet to be identified; (b) the limitations of the present experimental models, which suggest greater caution in the interpretation of in vitro results; (c) the still unresolved question of absence of genotype-phenotype correlation. Clarification of these issues may hopefully provide new and useful tools for improving the clinical management of this disease.


online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12804102&dopt=Abstract [PubMed - in process]



Thyroid. 2003 Apr;13(4):347-56.
Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.

Mikosch P, Obermayer-Pietsch B, Jost R, Jauk B, Gallowitsch HJ, Kresnik E, Leb G, Lind P.

Department of Nuclear Medicine and Special Endocrinology, Klagenfurt State Hospital, Austria. Peter.Mikosckh-klu.at

AIM: Patients with differentiated thyroid carcinoma (DTC) must receive suppressive levothyroxine (LT(4)) therapy for the rest of their lives. The literature, however, presents conflicting results on how this affects bone metabolism. The aim of this study was to assess the influence of the estrogen status and LT(4) therapy, in particular LT(4) dosage in micrograms per kilograms (microg/kg), on bone metabolism in female patients with DTC. MATERIAL AND METHODS: Three markers of bone metabolism (C-terminal telopeptide of type I collagen in serum [SCTx]; N-terminal telopeptide of type I collagen in urine [U-NTx]; and osteocalcin [OC]) were investigated in four groups: group REF (healthy premenopausal female controls), group DTC-ES (premenopausal women with DTC and normal estrogen levels), group DTC-ED (postmenopausal women with DTC and estrogen deficiency), and group DTC-HRT (postmenopausal women with DTC undergoing hormone replacement therapy [HRT]). All patients with DTC were on a well-adjusted suppressive LT(4) therapy with TSH levels 0.1 mU/L or less. RESULTS: In group DTC-ES bone turnover was comparable to group REF, whereas in group DTC-ED, all three markers were significantly increased as compared to groups REF and DTC-ES. In group DTC-HRT, the HRT normalized U-NTx and OC. However, in this group S-CTx was not completely normalized by HRT in all patients, although also significantly lowered compared to group DTC-ED. The analysis of LT(4 )dosage per kilogram showed that premenopausal DTC-patients had increased markers of bone metabolism if LT(4) dosage exceeded 2.6 microg/kg. Estrogen-deficient patients with DTC, however, had a much lower critical LT(4) dosage, above which increased markers of bone metabolism were seen. CONCLUSION: A well-adjusted suppressive LT(4) therapy of less than 2.6 microg/kg and normal estrogen levels do not seem to increase bone metabolism in estrogen-sufficient patients with DTC. The normalization of an estrogen deficiency by HRT or other antiresorptive therapies and minimal suppressive dosages of LT(4) are attempts to optimize the care of patients with DTC. In postmenopausal patients with DTC and patients with DTC who require LT(4) dosages in excess of 2.6 microg/kg, the information provided by markers of bone metabolism may help to prevent bone damage.


online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12804103&dopt=Abstract [PubMed - in process]



Thyroid. 2003 Apr;13(4):357-64.
The effects of triiodothyronine on bone metabolism in healthy ambulatory men.

Smith SR, Lovejoy JC, Rood J, Most M, Wickersham PJ, Volaufova J, Ryan D, Tulley R, Bray GA.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA. smithshs.pbrc.edu

The purpose of the present study was to determine the effects of supraphysiologic doses of triiodothyronine (T(3)) on skeletal metabolism, calcium balance, and the calciotropic hormones. Seven healthy, lean men were studied in an inpatient metabolic unit over a 63-day period. All volunteers received oral T(3) at doses of 50-75 microg/d. There was a prompt and sustained increase in calciuria and an overall net negative calcium balance. The pattern of changes in serum osteocalcin, urinary deoxypyridinoline (DPD)/creatinine ratio, and serum bone-specific alkaline phosphatase indicated an early increase in bone resorption followed by a late, incomplete compensatory increase in bone formation. Cumulative net calcium loss was 18.5 +/- 5.4 g over the 63-day treatment period, averaging 218.5 +/- 41.4 mg/d. This represents 0.22% +/- 0.075% of the total skeletal calcium content. The cumulative net calcium loss over the 63-day treatment period was highly correlated with the change in DPD (r = -0.95, p = 0.001). Prompt increases in corrected serum calcium values resulted in serum intact parathyroid hormone (iPTH) levels decreasing by 30.4% (p = 0.08). Bone mineral density showed no change. We conclude that T(3) accelerates bone turnover and that bone formation does not increase acutely to prevent bone loss.


online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12804104&dopt=Abstract [PubMed - in process]



Reprod Biomed Online. 2000;1(2):38-44.
Blood biochemistry and endocrinology in the human fetus between 11 and 17 weeks of gestation.

Jauniaux E, Pahal G, Gervy C, Gulbis B.

Academic Department of Obstetrics and Gynaecology, University College London Medical School, 86-96 Chenies Mews, London WC1E 6HX, UK.

Fetal blood was obtained in 35 normal pregnancies undergoing termination for psychosocial reasons between 11 and 17 weeks of gestation. Biochemical and endocrinological analyses were performed on each sample including concentrations of urea, creatinine, beta-microglobulin total protein, electrolytes, enzymes, alpha-fetoprotein (AFP), human chorionic gonadotrophin (HCG), thyroid stimulating hormone (TSH), thyroxin binding globulin (TBG), total thyroxin (TT4) and free thyroxin (FT4). The results were compared with values in maternal serum obtained at the same time. Fetal serum contained significantly higher concentrations of iron, beta-microglobulin, alkaline phosphatase (ALP), aspartate amniotransferase (AST), AFP, HCG and TSH and lower concentration of total protein, TBG and TT4 than maternal serum. Significant positive linear relationships were found between gestational age and the concentration of fetal serum total protein, ALP, TBG and FT4. Significant negative linear relationships were observed between gestational age and fetal serum beta-microglobulin and iron concentration. There were no significant correlations between fetal and maternal values. These data indicate that fetal blood biochemistry is not directly related to placental transfer and that the proteins and enzymes found inside the gestational sac are essentially of feto-placental origin with minimal contribution from the maternal protein metabolism. The comparison of coelomic fluid composition at 10-13 weeks with that of fetal serum at 11-17 weeks suggests that the anatomical changes in the human materno-fetal interface architecture between the early and late pregnancy periods could have a direct impact on materno-fetal transfer pathways.


online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12804197&dopt=Abstract [PubMed]



Reprod Biomed Online. 2000;1(2):48-62.
Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins.

Ulloa-Aguirre A, Timossi C.

Unidad de Investigacion, IMSS, Apartado Postal 99-065, Unidad Independencia Mexico 10101, D.F., Mexico.

Reproductive function in mammals is governed by the hypothalamic-pituitary-gonadal axis, which conforms a functional unit. Sexual maturation and the subsequent development of reproductive competence depend on the precise and coordinated function of this axis. The components of the reproductive axis communicate each other through endocrine signals. The hypothalamus synthesizes gonadotrophin-releasing hormone or GnRH, which in turn stimulates synthesis and secretion of the pituitary gonadotrophins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The ovarian follicles and the interstitial and Sertoli cells of the testis are the targets for these pituitary signals. Under gonadotrophic stimulation, the gonads produce and secrete several steroid and non-steroid (polypeptide) factors, which in turn regulate in different ways the function of the hypothalamic-pituitary axis. An episodic and pulsatile mode of secretion of hormonal signals characterize (as in other endocrine systems) the function of the reproductive axis, particularly that of the hypothalamic-pituitary unit. The target cell response, and consequently the harmonic function of the corresponding gland, will depend on the adequate dynamics of this pulsatile secretion. The function of each component of the reproductive axis is strongly influenced by locally-produced signals acting either in a paracrine or autocrine manner; these particular signals represent fine-tuning regulation systems that eventually amplify or restrain the magnitude of response to a particular endocrine signal, providing additional mechanisms for tissue homeostasis and a better functional plasticity of the target gland. The design and rational use of novel therapeutic strategies for an optimal exogenously-controlled reproductive function largely depend on the detailed knowledge of the hypothalamic-pituitary-gonadal axis function and the structure and mechanism of action of those factors and signals involved in its regulation.


online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12804199&dopt=Abstract [PubMed]








Natural Herbal Supplement: Hair Million


Hair loss alone does not pose significant health problems. In fact, there are people who opt for baldness as an alternative hair style. However, in general, however, hair loss is not considered desirable.

The most ostensive feature that distinguishes us human from chimps and other primates is the lack of bodily hair. During evolutionary process, we have lost the majority of hair. Hair is no longer a biologically essential part of our body, just like appendix. The hair we still have on our scalp and a few other bodily parts is still regarded as significant for reasons other than biological necessity. Hair loss is naturally accompanied by aging process, although the extent of hair loss and the timing of onset vary widely among individuals. Thus, loss of hair and baldness is considered as a symbol of maturity or old age. Like winkles and other signs of aging, hair loss is not welcome by most people, because we don't welcome aging, and being perceived as an aging person. However, it is alopecia, or premature hair loss that especially concerns certain people.

While the hair loss and resulting baldness in general have not been proven to be related to underlying health problems, there are certain correlations between hair loss and health problems. For instance, premature hair loss could suggest premature aging or nutritional and hormonal imbalance, stressful life, use of drugs that cause hair loss as a side effect, skin disease, or heart disease. The balding appearance could also impart a subdued impression of integrity in bodily health and youthfulness.














DreamPharm Online Healthy Supplements || Constipation relief, laxative, colon cleansing || Lutein || Progesterone Cream || Natural herbal formula for hair loss problems ||